Ombitasvir / paritaprevir / ritonavir / dasabuvir ± ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .
DSpace/Manakin Repository
Ombitasvir / paritaprevir / ritonavir / dasabuvir ± ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .
| Title: | Ombitasvir / paritaprevir / ritonavir / dasabuvir ± ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina . |
| Author: | Mendizabal, Manuel.; Haddad, Leila.; Gallardo, Patricia.; Ferrada, Alejandro.; Soza, Alejandro.; Adrover, Raul.; Aravena, Edmundo. |
| Abstract: | Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real-world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child-Pugh B at baseline and one patient died due to multi-organ failure. Follow up HCV-RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child-Pugh A cirrhosis in non-European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child-Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region. |
| URI: | https://riu.austral.edu.ar/handle/123456789/819 |
| Date: | 2017-03-29 |
Files in this item
| Files | Size | Format | View | Description |
|---|---|---|---|---|
| J Med Virol. 2017 Sep;89(9);1590-1596..pdf | 114.0Kb |
View/ |
IA - Mendizabal |
This item appears in the following Collection(s)
Todos los trabajos de el RIUAustral se encuentran protegidos por Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional aunque los autores pueden especificar otra licencia al enviar sus trabajos.
Ver Misión y Politicas del RIUAustral